Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

4.20USD
21 Sep 2018
Change (% chg)

-- (--)
Prev Close
$4.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
291,198
52-wk High
$16.46
52-wk Low
$4.10

Summary

Name Age Since Current Position

Bryan Roberts

51 2009 Independent Chairman of the Board

Kenneth Hillan

57 2018 President, President - R&D and Director

Blake Wise

47 2018 Chief Executive Officer, Director

Tobin Schilke

43 2016 Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Elizabeth Bhatt

50 2018 Chief Operating Officer

Lee Swem

42 2017 Senior Vice President, Chief Scientific Officer

Gary Loeb

48 2017 Chief Compliance Officer, General Counsel, Secretary

Janet Dorling

2017 Chief Commercial Officer

Karen Bernstein

65 2017 Independent Director

John Doyle

49 2016 Independent Director

Michael Fischbach

37 2016 Independent Director

Halley Gilbert

48 2017 Independent Director

Kent Lieginger

66 2015 Independent Director

John Smither

65 2014 Independent Director

Gregory Stea

60 2015 Independent Director

Biographies

Name Description

Bryan Roberts

Dr. Bryan E. Roberts, Ph.D., is Independent Chairman of the Board of the Company. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he currently serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts also currently serves as the chairman of the board of Castlight as well as a chairman and director of several private companies. Dr. Roberts previously served on the board of directors of publicly traded Athenahealth, Inc. from 1999 to 2009, XenoPort, Inc., from 2000 to 2007, Sirna Therapeutics, Inc. from 2003 to 2007, Vitae Pharmaceuticals, Inc. from 2001 to 2016, Zeltiq Aethetics, Inc. from 2008 to 2016 and Ironwood Pharmaceuticals, Inc. from 2001 to 2016. Dr. Roberts holds a B.A. in Chemistry from Dartmouth College and a Ph.D. in Chemistry and Chemical Biology from Harvard University.

Kenneth Hillan

Dr. Kenneth J. Hillan M.B. Ch.B. is no longer President, President - R&D and Director of the Company, effective October 15, 2018. He has served on the Board since October 2011. Dr. Hillan served as the Company’s Chief Medical Officer from April 2011 until July 2014, served as the Company’s President from October 2011 to February 2017 and has served as the Company’s Chief Executive Officer since October 2011. Prior to joining Achaogen, from 1994 to April 2011, Dr. Hillan served at Genentech. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair drug portfolio. For Genentech, he served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair, Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for F. Hoffmann-La Roche AG in Shanghai, China. Dr. Hillan served on the board of directors of Relypsa, Inc., a publicly traded biotechnology company, from June 2014 to September 2016 when it merged with Galenica AG. Dr. Hillan holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Blake Wise

Mr. Blake Wise is Chief Executive Officer, Director of the Achaogen Inc. effective on January 1, 2018. He has served as the Company’s President and Chief Operating Officer since February 2017 and served as the Company’s Chief Operating Officer from October 2015 to February 2017. From 2002 to August 2015, Mr. Wise served in roles of increasing responsibility at Genentech, including serving as Vice President, Cross BioOncology; Senior Director, Franchise Head and Life Cycle Leader, Lytics; Sales Director, BioOncology, Avastin; Marketing Director, Immunology and Cystic Fibrosis; and Director, Interactive Marketing. Mr. Wise currently serves as a director of Calithera Biosciences, Inc., a publicly traded oncological pharmaceutical company. Mr. Wise holds a B.A. from the University of California, Santa Barbara, and an M.B.A. from the University of California, Berkeley.

Tobin Schilke

Mr. Tobin Schilke is no longer Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective September 30, 2018. From 2002 to June 2016, Mr. Schilke served in roles of increasing responsibility at the Roche Group (including Genentech), a pharmaceutical company, including serving as Finance Director and Company Director of Roche Products Limited in the United Kingdom from August 2014 to June 2016 and serving as Director of Genentech’s Commercial Finance BioOncology Business Unit from September 2012 to August 2014. Mr. Schilke holds a B.S. from Lafayette College, a M.S. from the University of California, Berkeley and an M.B.A. from Cornell University’s Johnson Graduate School of Management.

Elizabeth Bhatt

Ms. Liz Bhatt is Chief Operating Officer of the Achaogen Inc. She joined Achaogen as Chief Business Officer in September 2017. Ms. Bhatt brings to Achaogen more than 20 years of experience in corporate development and strategy in the biopharmaceutical industry. Most recently, Ms. Bhatt held the positions of Vice President of Corporate Development (January 2016 to September 2017) and Senior Director of Corporate Development (May 2011 to December 2015) at Gilead Sciences, a biopharmaceutical company, where she was responsible for executing licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas. While at Gilead, she also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Eli Lilly and Company, a pharmaceutical company, and Maxygen, Inc., a biopharmaceutical company. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California at San Diego, and an M.B.A. from the Kellogg School of Management at Northwestern University.

Lee Swem

Dr. Lee Swem is no longer Senior Vice President, Chief Scientific Officer of the Company, effective September 24, 2018. From August 2014 to September 2015, Dr. Swem was Director of our Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem was with Genentech, where he served as a Consultant from August 2014 to August 2015 and a Scientist in Genentech’s Department of Infectious Disease from 2010 to August 2014. Dr. Swem completed his postdoctoral work at Princeton University. He received a B.S. in Biology and a Ph.D. in Microbiology from Indiana University.

Gary Loeb

Mr. Gary Loeb is Chief Compliance Officer, General Counsel, Secretary of the Achaogen Inc. He previously served as General Counsel of Sano Intelligence Inc., a medical device company, from November 2015 to June 2016, and as Executive Vice President, Business Development and General Counsel of Counsyl, Inc., a health technology company, where he worked from August 2013 to November 2015. Mr. Loeb worked for Amyris Inc., an industrial bioscience company, from 2011 to July 2013, where he served as served as General Counsel, Senior Vice President and Chief Compliance Officer. Prior to that, he was with Genentech, from 2000 to 2011, where he served as Vice President, Intellectual Property. From January 2006 to May 2015, Mr. Loeb was also an adjunct professor at University of San Francisco Law School. Mr. Loeb is currently on the board of directors for Project Open Hand, a nonprofit organization, and is on the Board of The Columbia Law School Association from 2016 through Summer 2018. Mr. Loeb holds a B.S. in Biology and a B.A. in English from Stanford University and a J.D. from Columbia Law School.

Janet Dorling

Ms. Janet Dorling is Chief Commercial Officer of the Achaogen Inc.

Karen Bernstein

Dr. Karen Bernstein is Independent Director of the Achaogen, Inc. Dr. Bernstein is currently the Chairman of BioCentury. From 1992 to September 2015, Dr. Bernstein was the Chairman and Editor-in-Chief of BioCentury where she wrote and published on biotechnology developments. Dr. Bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of The WorldVIEW 100 most influential people in biotech today by Scientific American (2015) and receiving a Special Recognition award at the American Liver Foundation’s Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation (2007). Dr. Bernstein served for many years as a member of the Brandeis University Science Advisory Council. She is on the board of trustees of the Keck Graduate Institute (“KGI”) of the Applied Life Sciences and is a member of the board of advisors of KGI’s School of Pharmacy. Dr. Bernstein is also a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain. From September 2015 to October 2016, she served on the board of directors of Vitae Pharmaceuticals Inc., which was acquired by Allergan plc. Dr. Bernstein holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University.

John Doyle

Mr. John C. Doyle is Independent Director of the Company. Mr. Doyle has been with Castlight Health, Inc., a healthcare technology company (“Castlight”) since November 2012, where he currently serves as Chief Executive Officer and previously served as President and Chief Operating Officer. Mr. Doyle served as Achaogen’s Chief Operating Officer from August 2009 to November 2009 and from February 2011 to November 2012, and as its Chief Financial Officer from November 2009 to February 2011. At Achaogen, Mr. Doyle managed business development, finance, IT and business strategy. Prior to joining Achaogen, Mr. Doyle was Vice President of Finance and Corporate Planning at Genentech, Inc., a biotechnology company and a member of the Roche Group (“Genentech”), from 2007 to 2009. Mr. Doyle is a member of the 2012 class of Henry Crown Fellows at the Aspen Institute. He holds a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo and an M.B.A. from the University of California, Berkeley.

Michael Fischbach

Dr. Michael Fischbach is Independent Director of the Company. Since May 2015, Since September 2017, Dr. Fischbach has served as an Associate Professor at Stanford University in the Department of Bioengineering and as a member of Stanford ChEM-H, an interdisciplinary institute that uses chemistry, engineering, and medicine to improve human health. Dr. Fischbach’s laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Prior to Stanford from September 2009 to September 2017, he was an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF, and prior to that he spent two years as an independent fellow at Massachusetts General Hospital. Dr. Fischbach is a recipient of the NIH Director's Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, and a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award. Dr. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in Chemistry from Harvard in 2007 and earned his A.B. in Biochemistry from Harvard.

Halley Gilbert

Ms. Halley E. Gilbert, Esq., is an Independent Director of the Company. Since 2008, Ms. Gilbert has served as Senior Vice President, Chief Legal Officer of Ironwood Pharmaceuticals, Inc., a publicly-traded biotechnology company. Prior to joining Ironwood, Ms. Gilbert was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. (“Cubist”) from 2002 to 2008, where she supported the launch of Cubist's first acute care antibiotic, and she served as Corporate Counsel at Genzyme Corp. from 1999 to 2001. Ms. Gilbert began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University.

Kent Lieginger

Dr. Kent E. Lieginger, Pharm.D., is Independent Director of the Company. Dr. Lieginger served as Senior Vice President, Managed Care and Customer Operations at Genentech from 2004 to July 2014 and as Director of the Genentech Foundation from 2010 to 2012. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech’s Commercial Leadership Committee. Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, a pharmaceutical company, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales. He has also served on the Board of Trustees at University of the Sciences in Philadelphia since 2013. He completed his residency in clinical pharmacy at the University of California in San Francisco and served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine.

John Smither

Mr. John Smither is an Independent Director of the Achaogen Inc. Since January 2016, Mr. Smither has served as Chief Financial Officer of Unity Biotechnology, Inc., a biotechnology company. From January 2016 to March 2017, Mr. Smither served as Chief Financial Officer of Sienna Biopharmaceuticals, Inc., a biotechnology company, where he continues to serve as a consultant since March 2017. Mr. Smither served as Chief Financial Officer of KYTHERA Biopharmaceuticals, Inc., a publicly traded biotechnology company, from November 2007 until it was acquired by Allergan, Inc. in October 2015. From 1998 to 2007, Mr. Smither held various positions at Amgen Inc., a publicly traded biotechnology company, including Executive Director of Corporate Accounting, Vice President of Finance and Administration of Amgen’s European Division, and Head of Internal Audit. Prior to joining Amgen, Mr. Smither served as an Audit Partner at Ernst & Young LLP, a public accounting firm. Following his time at Ernst & Young LLP, Mr. Smither served as the Chief Financial Officer of several early stage companies. Mr. Smither holds a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.

Gregory Stea

Mr. Gregory Stea is an Independent Director of Achaogen, Inc. Mr. Stea most recently served as Senior Vice President of Commercial Operations for Cubist from 2009 to February 2015, leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa and Sivextro. Prior to this, Mr. Stea served as Cubist’s Vice President, Sales and Marketing from 2007 to 2009. Having joined Cubist as an original member of the commercial organization, Mr. Stea served as Cubist’s Vice President of Sales from 2005 to 2007 and Executive Director of Sales from 2002 to 2005. Mr. Stea also served as a member of the Cubist Operating Committee from 2009 to February 2015, which was responsible for resource allocation, company strategy, risk management and compliance, among other responsibilities. He previously held leadership positions, including at the Vice President level, at Amgen Inc., a biotechnology company, from 1988 to 1997, where he was the first employee of its sales organization, responsible for the launch of Epogen and Neupogen. Mr. Stea holds a Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s Executive Education program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology.

Basic Compensation

Name Fiscal Year Total

Bryan Roberts

206,809

Kenneth Hillan

4,823,070

Blake Wise

2,701,610

Tobin Schilke

1,802,660

Elizabeth Bhatt

--

Lee Swem

1,458,430

Gary Loeb

458,000

Janet Dorling

--

Karen Bernstein

333,092

John Doyle

184,934

Michael Fischbach

180,434

Halley Gilbert

392,072

Kent Lieginger

184,434

John Smither

197,434

Gregory Stea

181,434
As Of  30 Dec 2017